Moreover, the combinational treatment with rapamycin and crizotinib leads to synergistic anti-tumor effects on EML4-ALK+ NSCLC cells as well as on those that acquired resistance to crizotinib. This evidence concerns the gene ALK and non-small cell lung carcinoma.